Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Market Access
  • Medicare Advantage in 2026: Enrollment Update and Key Trends
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

KFF Medicare

More than half (55%) of eligible Medicare beneficiaries are enrolled in Medicare Advantage in 2026.

Read full story

pharminent June 5, 2026 (Last updated: June 5, 2026)

KFF Medicare

More than half (55%) of eligible Medicare beneficiaries are enrolled in Medicare Advantage in 2026.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: The next FDA commissioner must be a champion for gene therapies
Next: Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization

Related Stories

  • Market Access

pharminent June 12, 2026
  • Market Access

Aquipta recommended by NICE for acute migraine treatment

pharminent June 10, 2026
  • Market Access

AbbVie’s migraine drug cleared for migraine attacks on NHS

pharminent June 10, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.